To validate PRMT5 as a target in GBM, we took advantage of a large unique and well-characterized cohort of patient-derived GSC lines grown either adherently on laminin (annotated “Gxxx”—29 lines) or grown as neurospheres (annotated “BTxxx”—17 lines). The gene discussed is PRMT5; the disease is glioblastoma.